Lapatinib plus trastuzumab in pretreated human epidermal growth factor receptor 2-positive metastatic breast cancer
| Autor: | Luis Manso, Santiago Cabezas, Cesar Mendiola, Ismael Ghanem, Eva Ciruelos, Hector Callata, Fernando Salvador Moreno, Miguel Sotelo, José A. García-Sáenz, Eduardo Díaz-Rubio |
|---|---|
| Rok vydání: | 2014 |
| Předmět: |
Adult
Oncology medicine.medical_specialty Receptor ErbB-2 medicine.medical_treatment Population Antineoplastic Agents Breast Neoplasms Human epidermal growth factor receptor 2-positive Lapatinib lcsh:RC254-282 Disease-Free Survival Drug Administration Schedule Trastuzumab Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Humans Radiology Nuclear Medicine and imaging Neoplasm Metastasis skin and connective tissue diseases education Adverse effect neoplasms Aged Retrospective Studies Aged 80 and over education.field_of_study Chemotherapy business.industry Retrospective cohort study General Medicine Middle Aged lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens medicine.disease Metastatic breast cancer Blockade Treatment Outcome pretreated patients Quinazolines Female metastatic breast cancer business medicine.drug |
| Zdroj: | Journal of Cancer Research and Therapeutics, Vol 10, Iss 4, Pp 967-972 (2014) |
| ISSN: | 0973-1482 |
| Popis: | Background: Dual human epidermal growth factor receptor 2 (HER2) blockade has been preclinically and clinically assessed in HER2-overexpressing metastatic breast cancer (mBC) with encouraging results. Patients and Methods: This is a descriptive retrospective study of trastuzumab plus lapatinib activity in patients with HER2-overexpressing mBC from two centers. The primary endpoints were to assess objective response rate (ORR) and toxicity. The secondary endpoints were to assess progression-free survival (PFS) and overall survival. Results: A total of 23 HER2-positive mBC patients previously treated with trastuzumab received a trastuzumab plus lapatinib based therapy. Chemotherapy (CT) was added to the dual HER2 blockade treatment in 13 patients (56%), whereas hormonotherapy (HT) was added in 8 patients (35%) and 2 patients (9%) received lapatinib plus trastuzumab without any other agent. ORR was 22% (5/23) and 39% (9/23) of patients had stable disease. PFS in the overall population was 4 months. PFS in patients with CT was 5 months, whereas PFS in patients with HT was 2 months. Grade ≥ 3 adverse events were diarrhea (26%) and hand-and-foot syndrome (9%). Conclusions: These findings suggest that dual HER2 blockade in combination with CT is feasible in pretreated HER2-positive mBC patients. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|